Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.

Teppei SuganoMasahiro SeikeYoshinobu SaitoTakeru KashiwadaYasuhiro TerasakiNatsuki TakanoKakeru HisakaneSatoshi TakahashiToru TanakaSusumu TakeuchiAkihiko MiyanagaYuji MinegishiRintaro NoroKaoru KubotaAkihiko Gemma

Published in: Thoracic cancer (2020)

ORR and PFS were significantly better in ILD patients than in irAEs-non-ILD and non-irAEs patients. Pre-existing history of IP was an independent risk factor for ILD-induced ICIs.

Keyphrases

end stage renal disease
advanced non small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
interstitial lung disease
prognostic factors
rheumatoid arthritis
systemic sclerosis
patient reported outcomes
drug induced
high glucose